Abstract

Arterial and venous thromboses are classically considered distinct disease states, with arterial thrombosis mediated predominantly by platelets and therefore, treated with antiplatelet therapy, and venous thrombosis mediated by the plasmatic coagulation system and treated with anticoagulation. However, co-occurrence of arterial and venous events is common, and there is increasing evidence of shared risk factors and pathophysiologic overlap. This presents a management challenge: does the patient with venous and arterial thrombosis, require anticoagulation, antiplatelet therapy, or both? Herein, we present a structured approach to the evaluation and management of patients with venous thrombosis who are also at risk for or have a history of an arterial thromboembolic event. We emphasize the importance of defining the indications for antithrombotic therapy, as well as the evaluation of factors that influence both thrombotic and bleeding risk, including disorder-specific and patient-specific factors, as well as the inherent risk balance of antithrombotic therapy regimens. We illustrate this approach in 4 cases, discussing the unique considerations and recent updates in the management of venous thrombosis, acute noncardioembolic ischemic stroke, coronary artery disease and acute myocardial infarction, and peripheral artery disease after revascularization.

1.
Mackman
N
.
Triggers, targets and treatments for thrombosis
.
Nature
.
2008
;
451
(
7181
):
914
-
918
.
2.
Piazza
G
,
Fanikos
J
,
Zayaruzny
M
,
Goldhaber
SZ
.
Venous thromboembolic events in hospitalised medical patients
.
Thromb Haemost
.
2009
;
102
(
3
):
505
-
510
.
3.
Rinde
LB
,
Lind
C
,
Småbrekke
B
, et al
.
Impact of incident myocardial infarction on the risk of venous thromboembolism: the Tromsø Study
.
J Thromb Haemost
.
2016
;
14
(
6
):
1183
-
1191
.
4.
Sørensen
H
,
Horvath-Puho
E
,
Pedersen
L
,
Baron
J
,
Prandoni
P
.
Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study
.
Lancet
.
2007
;
370
(
9601
):
1773
-
1779
.
5.
Becattini
C
,
Vedovati
MC
,
Ageno
W
,
Dentali
F
,
Agnelli
G
.
Incidence of arterial cardiovascular events after venous thromboembolism: a systematic review and a meta-analysis
.
J Thromb Haemost
.
2010
;
8
(
5
):
891
-
897
.
6.
Prandoni
P
,
Ghirarduzzi
A
,
Prins
MH
, et al
.
Venous thromboembolism and the risk of subsequent symptomatic atherosclerosis
.
J Thromb Haemost
.
2006
;
4
(
9
):
1891
-
1896
.
7.
Prandoni
P
,
Bilora
F
,
Marchiori
A
, et al
.
An association between atherosclerosis and venous thrombosis
.
N Engl J Med
.
2003
;
348
(
15
):
1435
-
1441
.
8.
Ageno
W
,
Becattini
C
,
Brighton
T
,
Selby
R
,
Kamphuisen
PW
.
Cardiovascular risk factors and venous thromboembolism
.
Circulation
.
2008
;
117
(
1
):
93
-
102
.
9.
Ageno
W
,
Prandoni
P
,
Romualdi
E
, et al
.
The metabolic syndrome and the risk of venous thrombosis: a case-control study
.
J Thromb Haemost
.
2006
;
4
(
9
):
1914
-
1918
.
10.
Lowe
GDO
.
Common risk factors for both arterial and venous thrombosis
.
Br J Haematol
.
2008
;
140
(
5
):
488
-
495
.
11.
Matharu
GS
,
Kunutsor
SK
,
Judge
A
,
Blom
AW
,
Whitehouse
MR
.
Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement
.
JAMA Intern Med
.
2020
;
180
(
3
):
376
-
384
.
12.
Eikelboom
JW
,
Connolly
SJ
,
Bosch
J
, et al
.
Rivaroxaban with or without aspirin in stable cardiovascular disease
.
N Engl J Med Overseas Ed
.
2017
;
377
(
14
):
1319
-
1330
.
13.
Bonaca
MP
,
Bauersachs
RM
,
Anand
SS
, et al
.
Rivaroxaban in peripheral artery disease after revascularization
.
N Engl J Med
.
2020
;
382
(
21
):
1994
-
2004
.
14.
Berkowitz
SD
,
Bauersachs
RM
,
Szarek
M
, et al
.
Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone
.
J Thromb Haemost
.
2022
;
20
(
5
):
1193
-
1205
.
15.
Lopes
RD
,
Heizer
G
,
Aronson
R
, et al
.
Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation
.
N Engl J Med
.
2019
;
380
(
16
):
1509
-
1524
.
16.
Alexander
JH
,
Lopes
RD
,
James
S
, et al
.
Apixaban with antiplatelet therapy after acute coronary syndrome
.
N Engl J Med
.
2011
;
365
(
8
):
699
-
708
.
17.
Mega
JL
,
Braunwald
E
,
Wiviott
SD
, et al
.
Rivaroxaban in patients with a recent acute coronary syndrome
.
N Engl J Med
.
2012
;
366
(
1
):
9
-
19
.
18.
Gori
T
,
Polimeni
A
,
Indolfi
C
,
Raber
L
,
Adriaenssens
T
,
Munzel
T
.
Predictors of stent thrombosis and their implications for clinical practice
.
Nat Rev Cardiol
.
2019
;
16
(
4
):
243
-
256
.
19.
Marsh
EB
,
Llinas
RH
,
Schneider
ALC
, et al
.
Predicting hemorrhagic transformation of acute ischemic stroke: prospective validation of the HeRS score
.
Medicine (Baltimore)
.
2016
;
95
(
2
):
e2430
.
20.
Klok
FA
,
Huisman
MV
.
How I assess and manage the risk of bleeding in patients treated for venous thromboembolism
.
Blood
.
2020
;
135
(
10
):
724
-
734
.
21.
Den Exter
PL
,
Woller
SC
,
Robert-Ebadi
H
, et al
.
Management of bleeding risk in patients who receive anticoagulant therapy for venous thromboembolism: communication from the ISTH SSC Subcommittee on Predictive and Diagnostic Variables in Thrombotic Disease
.
J Thromb Haemost
.
2022
;
20
(
8
):
1910
-
1919
.
22.
Urban
P
,
Mehran
R
,
Colleran
R
, et al
.
Defining high bleeding risk in patients undergoing percutaneous coronary intervention
.
Circulation
.
2019
;
140
(
3
):
240
-
261
.
23.
Lane
DA
,
Lip
GYH
.
Stroke and bleeding risk stratification in atrial fibrillation: a critical appraisal
.
Eur Heart J Suppl
.
2020
;
22
(
suppl O
):
O14
-
O27
.
24.
Guirguis-Blake
JM
,
Evans
CV
,
Perdue
LA
,
Bean
SI
,
Senger
CA
.
Aspirin use to prevent cardiovascular disease and colorectal cancer: updated evidence report and systematic review for the US Preventive Services Task Force
.
JAMA
.
2022
;
327
(
16
):
1585
-
1597
.
25.
Arnett
DK
,
Blumenthal
RS
,
Albert
MA
, et al
.
ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
.
Circulation
.
2019
;
140
(
11
):
e563
-
e595
.
26.
US Preventive Services Task Force
.
Aspirin use to prevent cardiovascular disease: US Preventive Services Task Force Recommendation Statement
.
JAMA
.
2022
;
327
(
16
):
1577
-
1584
.
27.
Schaefer
JK
,
Errickson
J
,
Li
Y
, et al
.
Adverse events associated with the addition of aspirin to direct oral anticoagulant therapy without a clear indication
.
JAMA Intern Med
.
2021
;
181
(
6
):
817
-
824
.
28.
Schaefer
JK
,
Li
Y
,
Gu
X
, et al
.
Association of adding aspirin to warfarin therapy without an apparent indication with bleeding and other adverse events
.
JAMA Intern Med
.
2019
;
179
(
4
):
533
-
541
.
29.
Feldmann
K
,
Grandoch
M
,
Kohlmorgen
C
, et al
.
Decreased M1 macrophage polarization in dabigatran-treated Ldlr-deficient mice: implications for atherosclerosis and adipose tissue inflammation
.
Atherosclerosis
.
2019
;
287
:
81
-
88
.
30.
Lee
J
,
Nakanishi
R
,
Li
D
, et al
.
Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis
.
Am Heart J
.
2018
;
206
:
127
-
130
.
31.
Yasuda
S
,
Kaikita
K
,
Akao
M
, et al
.
Antithrombotic therapy for atrial fibrillation with stable coronary disease
.
N Engl J Med
.
2019
;
381
(
12
):
1103
-
1113
.
32.
Schaefer
JK
,
Errickson
J
,
Gu
X
, et al
.
Assessment of an intervention to reduce aspirin prescribing for patients receiving warfarin for anticoagulation
.
JAMA Netw Open
.
2022
;
5
(
9
):
e2231973
.
33.
de Winter
MA
,
Buller
HR
,
Carrier
M
, et al
.
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
.
Eur Heart J
.
2023
;
44
(
14
):
1231
-
1244
.
34.
Kearon
C
,
Kahn
SR
.
Long-term treatment of venous thromboembolism
.
Blood
.
2020
;
135
(
5
):
317
-
325
.
35.
Stevens
SM
,
Woller
SC
,
Kreuziger
LB
, et al
.
Antithrombotic therapy for VTE disease: second update on the CHEST Guideline and Expert Panel Report
.
Chest
.
2021
;
160
(
6
):
e545
-
e608
.
36.
Ortel
TL
,
Neumann
I
,
Ageno
W
, et al
.
American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism
.
Blood Adv
.
2020
;
4
(
19
):
4693
-
4738
.
37.
Agnelli
G
,
Buller
HR
,
Cohen
A
, et al
.
Apixaban for extended treatment of venous thromboembolism
.
N Engl J Med
.
2013
;
368
(
8
):
699
-
708
.
38.
Weitz
JI
,
Lensing
AWA
,
Prins
MH
, et al
.
Rivaroxaban or aspirin for extended treatment of venous thromboembolism
.
N Engl J Med
.
2017
;
376
(
13
):
1211
-
1222
.
39.
Ray
JG
,
Mamdani
M
,
Tsuyuki
RT
,
Anderson
DR
,
Yeo
EL
,
Laupacis
A
.
Use of statins and the subsequent development of deep vein thrombosis
.
JAMA Int Med
.
2001
;
161
(
11
):
1405
-
1410
.
40.
Stewart
LK
,
Sarmiento
EJ
,
Kline
JA
.
Statin use is associated with reduced risk of recurrence in patients with venous thromboembolism
.
Am J Med
.
2020
;
133
(
8
):
930
-
935.e8
.
41.
Horvei
LD
,
Brækkan
SK
,
Hansen
J-B
.
Weight change and risk of venous thromboembolism: the Tromsø Study
.
PLoS One
.
2016
;
11
(
12
):
e0168878
.
42.
Vuckovic
BA
,
Cannegieter
SC
,
van Hylckama Vlieg
A
,
Rosendaal
FR
,
Lijfering
WM
.
Recurrent venous thrombosis related to overweight and obesity: results from the MEGA follow-up study
.
J Thromb Haemost
.
2017
;
15
(
7
):
1430
-
1435
.
43.
Ntinopoulou
P
,
Ntinopoulou
E
,
Papathanasiou
IV
, et al
.
Obesity as a risk factor for venous thromboembolism recurrence: a systematic review
.
Medicina
.
2022
;
58
(
9
):
1290
.
44.
Powers
WJ
,
Rabinstein
AA
,
Ackerson
T
, et al
.
Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke
.
Stroke
.
2019
;
50
(
12
):
e344
-
e418
.
45.
Brown
DL
,
Levine
DA
,
Albright
K
, et al
.
Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack
.
Stroke
.
2021
;
52
(
7
):
e468
-
e479
.
46.
Kleindorfer
DO
,
Towfighi
A
,
Chaturvedi
S
, et al
.
Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association
.
Stroke
.
2021
;
52
(
7
):
e364
-
e467
.
47.
De Schryver
E
,
Algra
A
,
Kappelle
LJ
,
van Gijn
J
,
Koudstaal
P
.
Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin
.
Cochrane Database Syst Rev
.
2012
;
2012
(
9
):
CD001342
.
48.
Hart
RG
,
Sharma
M
,
Mundl
H
, et al
.
Rivaroxaban for stroke prevention after embolic stroke of undetermined source
.
N Engl J Med
.
2018
;
378
(
23
):
2191
-
2201
.
49.
Kumbhani
DJ
,
Cannon
CP
,
Beavers
CJ
, et al
.
ACC Expert Consensus decision pathway for anticoagulant and antiplatelet therapy in patients with atrial fibrillation or venous thromboembolism undergoing percutaneous coronary intervention or with atherosclerotic cardiovascular disease: a report of the American College of Cardiology Solution Set Oversight Committee
.
J Am Coll Cardiol
.
2021
;
77
(
5
):
629
-
658
.
50.
Ray
WA
,
Chung
CP
,
Murray
KT
, et al
.
Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding
.
JAMA
.
2018
;
320
(
21
):
2221
-
2230
.
51.
Kurlander
JE
,
Barnes
GD
,
Fisher
A
, et al
.
Association of antisecretory drugs with upper gastrointestinal bleeding in patients using oral anticoagulants: a systematic review and meta-analysis
.
Am J Med
.
2022
;
135
(
10
):
1231
-
1243.e8
.
52.
Moayyedi
P
,
Eikelboom
JW
,
Bosch
J
, et al
.
Pantoprazole to prevent gastroduodenal events in patients receiving rivaroxaban and/or aspirin in a randomized, double-blind, placebo-controlled trial
.
Gastroenterology
.
2019
;
157
(
2
):
403
-
412.e5
.
53.
Valgimigli
M
,
Bueno
H
,
Byrne
RA
, et al
.
ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
.
Eur Heart J
.
2018
;
39
(
3
):
213
-
260
.
54.
Klok
FA
,
Barco
S
,
Turpie
AGG
, et al
.
Predictive value of venous thromboembolism (VTE)-BLEED to predict major bleeding and other adverse events in a practice-based cohort of patients with VTE: results of the XALIA study
.
Br J Haematol
.
2018
;
183
(
3
):
457
-
465
.
55.
Pisters
R
,
Lane
DA
,
Nieuwlaat
R
,
de Vos
CB
,
Crijns
HJ
,
Lip
GY
.
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey
.
Chest
.
2010
;
138
(
5
):
1093
-
1100
.
56.
Levine
GN
,
Bates
ER
,
Bittl
JA
, et al
.
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and mangement of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery
.
Circulation
.
2016
;
134
(
10
):
e123
-
e155
.
57.
McFadden
EP
,
Stabile
E
,
Regar
E
, et al
.
Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy
.
Lancet
.
2004
;
364
(
9444
):
1519
-
1521
.
58.
January
CT
,
Wann
LS
,
Calkins
H
, et al
.
AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society
.
Circulation
.
2019
;
140
(
2
):
e66
-
e93
.
59.
Lip
GYH
,
Collet
J-P
,
Haude
M
, et al
.
Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions
.
Europace
.
2019
;
21
(
2
):
192
-
193
.
60.
Angiolillo
DJ
,
Goodman
SG
,
Bhatt
DL
, et al
.
Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention
.
Circulation
.
2018
;
138
(
5
):
527
-
536
.
61.
Smits
PC
,
Frigoli
E
,
Tijssen
J
, et al
.
Abbreviated antiplatelet therapy in patients at high bleeding risk with or without oral anticoagulant therapy after coronary stenting: an open-label, randomized, controlled trial
.
Circulation
.
2021
;
144
(
15
):
1196
-
1211
.
62.
De Caterina
R
,
Agewall
S
,
Andreotti
F
, et al
.
Great debate: triple antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting should be limited to 1 week
.
Eur Heart J
.
2022
;
43
(
37
):
3512
-
3527
.
63.
Sardar
P
,
Chatterjee
S
,
Lavie
CJ
, et al
.
Risk of major bleeding in different indications for new oral anticoagulants: Insights from a meta-analysis of approved dosages from 50 randomized trials
.
Int J Cardiol
.
2015
;
179
:
279
-
287
.
64.
Gibson
CM
,
Mehran
R
,
Bode
C
, et al
.
Prevention of bleeding in patients with atrial fibrillation undergoing PCI
.
N Engl J Med
.
2016
;
375
(
25
):
2423
-
2434
.
65.
Cannon
CP
,
Bhatt
DL
,
Oldgren
J
, et al
.
Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
.
N Engl J Med
.
2017
;
377
(
16
):
1513
-
1524
.
66.
Gerhard-Herman
MD
,
Gornik
HL
,
Barrett
C
, et al
.
AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
.
Circulation
.
2017
;
135
(
12
):
1465
-
1508
.
67.
Aboyans
V
,
Ricco
J-B
,
Bartelink
M-LEL
, et al
.
ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS)
.
Eur Heart J
.
2018
;
39
(
9
):
763
-
816
.
68.
Abramson
BL
,
Al-Omran
M
,
Anand
SS
, et al
.
Canadian Cardiovascular Society 2022 guidelines for peripheral arterial disease
.
Can J Cardiol
.
2022
;
38
(
5
):
560
-
587
.
69.
McClure
GR
,
Kaplovitch
E
,
Chan
N
, et al
.
A National Canadian Survey of antithrombotic therapy after urgent and emergent limb revascularization
.
Can J Cardiol
.
2021
;
37
(
3
):
504
-
507
.
70.
Hess
CN
,
Szarek
M
,
Anand
SS
, et al
.
Rivaroxaban and risk of venous thromboembolism in patients with symptomatic peripheral artery disease after lower extremity revascularization
.
JAMA Netw Open
.
2022
;
5
(
6
):
e2215580
.
71.
Pogosova
N
,
Bosch
J
,
Bhatt
DL
, et al
.
Rivaroxaban 2.5 mg twice daily plus aspirin reduces venous thromboembolism in patients with chronic atherosclerosis
.
Circulation
.
2022
;
145
(
25
):
1875
-
1877
.
72.
Aziz
F
,
Patel
M
,
Ortenzi
G
,
Reed
AB
.
Incidence of postoperative deep venous thrombosis is higher among cardiac and vascular surgery patients as compared with general surgery patients
.
Ann Vasc Surg
.
2015
;
29
(
4
):
661
-
669
.
73.
Kindell
DG
,
Duchesneau
EG
,
Browder
SE
, et al
.
Incidence of venous thromboembolism in patients with peripheral arterial disease after endovascular intervention
.
J Vasc Surg
.
2022
;
75
(
1
):
E29
-
30
.
74.
Steinberg
BA
,
Shrader
P
,
Pieper
K
, et al
.
Frequency and outcomes of reduced dose non–vitamin K antagonist anticoagulants: results from ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II)
.
J Am Heart Assoc
.
2018
;
7
(
4
):
e007633
.
75.
Santos
J
,
António
N
,
Rocha
M
,
Fortuna
A
.
Impact of direct oral anticoagulant off-label doses on clinical outcomes of atrial fibrillation patients: a systematic review
.
Br J Clin Pharmacol
.
2020
;
86
(
3
):
533
-
547
.
76.
Weitz
JI
,
Eikelboom
JW
.
Appropriate apixaban dosing: prescribers take note
.
JAMA Cardiol
.
2016
;
1
(
6
):
635
-
636
.
77.
Camm
AJ
,
Cools
F
,
Virdone
S
, et al
.
Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants
.
J Am Coll Cardiol
.
2020
;
76
(
12
):
1425
-
1436
.
78.
Trujillo-Santos
J
,
Di Micco
P
,
Dentali
F
, et al
.
Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens
.
Thromb Haemost
.
2017
;
117
(
2
):
382
-
389
.
79.
Sanghai
S
,
Wong
C
,
Wang
Z
, et al
.
Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF Study
.
J Am Heart Assoc
.
2020
;
9
(
6
):
e014108
.
80.
Howard
M
,
Lipshutz
A
,
Roess
B
, et al
.
Identification of risk factors for inappropriate and suboptimal initiation of direct oral anticoagulants
.
J Thromb Thrombolysis
.
2017
;
43
(
2
):
149
-
156
.
81.
Viprey
M
,
Jeannin
R
,
Piriou
V
, et al
.
Prevalence of drug-related problems associated with direct oral anticoagulants in hospitalized patients: a multicenter, cross-sectional study
.
J Clin Pharm Ther
.
2017
;
42
(
1
):
58
-
63
.
82.
Miele
C
,
Taylor
M
,
Shah
A
.
Assessment of direct oral anticoagulant prescribing and monitoring pre- and post-implementation of a pharmacy protocol at a community teaching hospital
.
Hosp Pharm
.
2017
;
52
(
3
):
207
-
213
.
83.
Reardon
DP
,
Atay
JK
,
Ashley
SW
,
Churchill
WW
,
Berliner
N
,
Connors
JM
.
Implementation of a hemostatic and antithrombotic Stewardship program
.
J Thromb Thrombolysis
.
2015
;
40
(
3
):
379
-
382
.
84.
Cutlip
DE
,
Windecker
S
,
Mehran
R
, et al
.
Clinical end points in coronary stent trials
.
Circulation
.
2007
;
115
(
17
):
2344
-
2351
.
85.
Joglar
JA
,
Chung
MK
,
Armbruster
AL
, et al
.
2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
.
J Am Coll Cardiol
.
2024
;
83
(
1
):
109
-
279
.
86.
Byrne
RA
,
Rossello
X
,
Coughlan
JJ
, et al
.
2023 ESC guidelines for the management of acute coronary syndromes
.
Eur Heart J Acute Cardiovasc Care
.
2024
;
13
(
1
):
55
-
161
.
87.
Burnett
AE
,
Barnes
GD
.
A call to action for anticoagulation stewardship
.
Res Pract Thromb Haemost
.
2022
;
6
(
5
):
e12757
.
You do not currently have access to this content.
Sign in via your Institution